Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement and Estimates

More financial data

Real-time BOERSE MUENCHEN Other stock markets 10:44:13 25/09/2025 +04			5-day change	1st Jan Change
0.0985 ^EUR	-0.51%		-.--%	-

01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today

Market Cap	6.15M 7.08M 5.67M 5.31M 9.92M 678M 10.12M 67.58M 26.16M 327M 26.59M 26.01M 1.14B	P/E Ratio 2023	-3.09x	P/E Ratio 2024	-0.95x
Enterprise Value	59.25M 68.27M 54.61M 51.17M 95.61M 6.54B 97.6M 651M 252M 3.15B 256M 251M 10.96B	EV / Sales 2023	56.1x	EV / Sales 2024	13.5x
Free-Float	89.06%	Yield 2023 *	-	Yield 2024	-

01-07	Carmat, Hoffmann, LDC, Pluxee, Technip Energies... Stocks to Watch Today in Paris
01-07	CARMAT: To Watch Today
01-06	Carmat, GTT, Genfit, LDC... Stocks to Watch Tomorrow in Paris
01-06	Carmat Announces Liquidation and Delisting
12-02	Only Takeover Bid for Carmat Approved by Court
12-02	Carmat: Takeover Offer Approved, 88 Jobs Saved	RE
12-02	Carmat receives takeover bid	RE
11-04	Carmat SAS submits bid for Carmat SA within ongoing receivership procedure	RE
15/10/25	CAC 40 Surges on LVMH Results and Easing US-China Tensions
15/10/25	Carmat: Judicial Recovery Continues, New Hearing Set for November 25	RE
15/10/25	Carmat says liquidation review postponed until Nov 25	RE
01/10/25	Carmat: Judicial Liquidation Request to Be Reviewed on October 14	RE
01/10/25	Carmat: Judiciary administrator has submitted request to convert receivership into liquidation to court	RE

09/05/25	Carmat: Invest Securities raises target price
11/04/25	Carmat: Invest Securities still a buyer, but cuts TP
04/02/25	Carmat: Invest Securities slightly lowers its target
09/01/25	Carmat: Invest Securities upgrades to buy
09/01/25	Carmat: Oddo BHF reduces its price target

CARMAT Stock BOERSE MUENCHEN

Stocks

CXT

FR0010907956

Medical Equipment, Supplies & Distribution

Valuation: CARMAT

Chart: CARMAT

Latest news : CARMAT

Analysts' recommendations: CARMAT

Press Releases: CARMAT

News in other languages: CARMAT

Quotes and Performance

Managers and Directors: CARMAT

Medical Devices & Implants

Financials

Company Profile

Income Statement and Estimates

12-02	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
11-04	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU
29/10/25	CARMAT : Inside Information / Other news releases	PU
29/10/25	CARMAT Announces Postponing the Publication of its 2025 Interim Financial Report (Six Months Ended June 30, 2025)	BU
15/10/25	CARMAT Provides an Update on the Ongoing Receivership Procedure	BU

03-04	Carmat, Ynsect… quand les pépites industrielles françaises tombent dans le gouffre de Moore
01-07	Pluxee N : Carmat, Hoffmann, LDC, Pluxee, Technip Energies... les valeurs à suivre aujourd'hui à Paris
01-07	Bourse : GTT et Technip Energy engrangent, Pluxee publie, Carmat disparaît
01-07	CARMAT : A suivre aujourd'hui
01-07	Les records continuent à tomber en bourse

Manager	Title	Age	Since
Stéphane Piat CEO	Chief Executive Officer	55	01/09/2016
Pascale d’Arbonneau DFI	Director of Finance/CFO	-	12/12/2018
Christian Latrémouille CTO	Chief Tech/Sci/R&D Officer	-	01/04/2025

Director	Title	Age	Since
Stéphane Piat BRD	Director/Board Member	55	-
Jean-Luc Lemercier BRD	Director/Board Member	68	02/01/2017
Michael Mack BRD	Director/Board Member	79	20/04/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARMAT	-0.51%	-.--%	-	-	7.08M
STRYKER CORPORATION	+1.62%	+1.38%	-18.56%	+10.71%	117B
SMITH & NEPHEW PLC	-0.11%	-0.92%	+2.43%	-4.09%	12.86B
GLAUKOS CORPORATION	+2.97%	+2.02%	+30.66%	+90.54%	7.29B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+1.87%	-3.51%	-46.74%	-69.06%	4.12B
DOUBLE MEDICAL TECHNOLOGY INC.	+2.06%	+5.59%	+11.04%	+33.01%	2.49B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	+5.46%	+10.30%	-16.96%	-14.78%	1.7B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+1.67%	-6.39%	+3.63%	-11.43%	1.63B
L&C BIO CO.,LTD	-8.89%	-8.45%	+165.17%	+112.14%	1.49B
Average	+0.69%	+1.07%	+16.34%	+18.38%	18.59B
Weighted average by Cap.	+1.50%	+1.39%	-12.51%	+11.99%

	2023	2024
Net sales	3.84M 4.42M 3.54M 3.31M 6.19M 423M 6.32M 42.19M 16.33M 204M 16.6M 16.24M 710M	7.34M 8.46M 6.77M 6.34M 11.85M 810M 12.1M 80.75M 31.26M 391M 31.77M 31.08M 1.36B
Net income	-53.87M -62.08M -49.66M -46.53M -86.93M -5.94B -88.74M -592M -229M -2.87B -233M -228M -9.96B	-51.4M -59.22M -47.37M -44.39M -82.94M -5.67B -84.67M -565M -219M -2.73B -222M -218M -9.5B
Net Debt	49.64M 57.2M 45.75M 42.87M 80.1M 5.48B 81.77M 546M 211M 2.64B 215M 210M 9.18B	53.1M 61.19M 48.95M 45.86M 85.69M 5.86B 87.48M 584M 226M 2.82B 230M 225M 9.82B